SK Biopharmaceuticals Settles XCOPRI U.S. Patent Dispute
SK Biopharmaceuticals announced on August 19 that it has reached an amicable settlement with the Indian generic company MSN Laboratories in a United States patent litigation regarding its innovative epilepsy drug cenobamate (U.S. product name: XCOPRI®). The specific conditions of the settlement rema
SK Biopharmaceuticals reached an agreement with Indian generic company MSN Laboratories on August 19 to settle a U.S. patent dispute over their epilepsy drug cenobamate, also known as XCOPRI®. The settlement details have not been disclosed, but SK Biopharmaceuticals has agreed to grant MSN Laboratories the right to market a generic version under the patent protection.
This settlement resolves pending patent litigation at the United States District Court for the District of Delaware, allowing the drug's patent protection to continue beyond the compound patent's expiration in 2032. The agreement aims to support the sustained growth and long-term market position of XCOPRI® in the United States.
Written by urgent.news from BusinessKorea's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
